Search

everythinglearnresearchcommunity

for

Search:↓

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

Sorafenib can cause a unique skin reaction.

The combination of encorafenib and binimetinib caused few skin issues.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Dihydrotestosterone (DHT) increases oil production in skin cells by activating mTOR, and mTOR inhibitors can reduce this effect.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

The rash resolved after stopping ponatinib.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

An 8-year-old girl with vitiligo developed extra hair growth on her knee after using tacrolimus ointment.

Methotrexate can temporarily suppress certain immune responses without killing immune cells, potentially helping treat autoimmune diseases.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Intralesional cidofovir might be a viable alternative treatment for certain conditions.

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.

Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

The drug combination was safe and showed promise in treating advanced tumors.

Ruxolitinib can help regrow hair in severe alopecia areata.

Dapagliflozin improved blood sugar control in a man with Werner syndrome without side effects.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Rituximab may be an effective treatment for Cronkhite-Canada syndrome with kidney disease.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

A protein complex called mTORC1 likely affects when hair growth starts in mice.

TSC2-/meth cells can cause skin lesions, hair growth, and lung issues, and may be treated with chromatin remodeling agents.